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ABSTRACT
Background and the purpose of the study: Lamotrigine is a broad spectrum anticonvulsant drug 
widely used as mono- or  adjunct- therapy in adults and children. The aim of this study was to 
develop controlled release liquid formulation of lamotrigine to improve bioavailability  and 
compliance of pediatric and geriatric epileptic patients. 
Methods: Multiple (w/o/w) emulsion was prepared using one step emulsification technique. It 
was evaluated for entrapment efficiency (EE), morphology, zeta potential (ZP), polydispersity 
index (PI), rheology, thermal property, in vitro drug release behavior and stability. In vivo 
studies in albino mice were carried out using maximal electroshock seizure (MES) test 
and strychnine induced seizure (SIS) pattern test and results were compared with marketed 
formulation. 
Results: The EE of the formulations varied from 84.37% to 98.11%. The ZP and PI values of 
the prepared batches were in the range of +23.46 to +28.07 and 0.256 and 0.365, respectively. 
Microscopic observation clearly indicated the stability of the emulsions during the storage 
period. All batches exhibited controlled in vitro drug release up to 12 hrs. Batch C11 exhibited 
significantly  longer  duration  of  protection  of  seizure  in  mice  against  MES  and  exhibited 
comparable efficacy in SIS as compared to the marketed formulation. 
Major Conclusion: Multiple emulsion of lamotrigine compared to the marketed tablet showed   
plasma drug concentration within therapeutic range for longer time and comparable efficacy. 
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INTRODUCTION
Epilepsy is a common chronic neurological disorder 
characterized by recurrent unprovoked seizures. 
These seizures are transient signs and/or symptoms 
of abnormal, excessive or synchronous neuronal 
activity in the brain. About 50 million people 
worldwide suffer from epilepsy; of which almost 
90% belong to developing countries. Although, 
the occurrence of epilepsy is uncertain, it is more 
likely to occur in young children or people above 
the age of 65 years. The prevalence of epilepsy 
has approximately an annual incidence rate of 
40–70 per 100,000 in industrialized countries and 
100–190 per 100,000 in resource-poor countries. 
Socioeconomically deprived people have been 
found to be at higher risk. In industrialized 
countries, the incidence rate has been found to be 
lower in children and higher among the elderly 
population (1). 
Currently, about 20 medications have been approved 
by the Food and Drug Administration, for the 
treatment of epileptic seizures (2). Among these, 
lamotrigine is a broad spectrum anticonvulsant drug 
widely used as mono- or adjunct -therapy in adults 
and children. The drug is currently available as a 
tablet which is administered 2-3 times per day as 
divided doses of 25-600 mg (3). Although, tablets 
are very simple to manufacture and handle, oral 
liquid formulations with additional sustained release 
properties (4) are always preferred for pediatric, 
geriatric even dysphagic patients, due to their ease 
of administration and patient compliance. even at 
the time of epileptic attack.
In the present investigation, multiple emulsion was 
chosen as a liquid drug delivery system because 
of several advantages offered by this system over 
other conventional systems. Apart from easy 
swallowability,  flexible  dosing  and  improved 
bioavailability, it has  capability  of controlling 
the release of the active ingredients which 
improves patient compliance and also reduces 
the  gastrointestinal  side  effects  significantly  by 
reducing the concentration of the drug exposed 
to the gastrointestinal mucosa (5, 6). The w/o/w 
multiple emulsion containing lamotrigine was 
developed and was evaluated for its physiochemical 
properties along with its anticonvulsant activity in 
mice.
126MATERIAL AND METHODS
Lamotrigine was provided as a gift from Glenmark 
Pharmaceuticals Ltd., (India). Light liquid paraffin 
was purchased from Reidel Chemicals (India), 
Tween 80 and Span 80 (Loba Chemie Pvt. Ltd. 
,India), glycerol (Qualigens Fine Chemicals India) 
and polyvinyl acetate and amaranth (Central Drug 
House India) were used in this study. Other chemicals 
of analytical grade were purchased locally and used 
as received.
Solubility studies
The solubility of the drug was determined in distilled 
water, acid buffer (pH 1.2), citrate buffer (pH 4.5) 
and phosphate buffer (pH 7.4). An excess amount of 
drug was added to 10 ml of each solvent in sealed 
glass vials and the resulting suspensions were stirred 
on a magnetic stirrer for 24 hrs at room temperature. 
Samples  were  then  filtered,  appropriately  diluted 
and analyzed by UV spectrophotometry (Shimadzu, 
Model 7800, Kyoto, Japan) at 265.5 nm. Each 
solubility value was determined in triplicate.
Determination  of  effective  hydrophilic  lipophilic 
balance (EHLB)
The optimal ratio of hydrophilic and lipophilic 
surfactant was determined from the EHLB values 
which were calculated using the following formula:
EHLB=HLBA×0.01A+ HLBB×0.01B          Equation 1
where A and B are the volume fraction of hydrophilic 
and lipophilic surfactants, respectively. 
Fabrication of lamotrigine formulations 
Four different formulations of lamotrigine were 
prepared, namely aqueous and oily drug suspension, 
simple emulsions (w/o and o/w) and multiple w/o/w 
emulsions, using liquid paraffin as the oil phase. The 
final volume of the formulations was 50 ml which 
contained 100 mg of lamotrigine (2 mg/ml). The 
compositions of all the batches prepared are given 
in table 1.
Preparation of aqueous and oily drug suspension
For aqueous drug suspension, 100 mg of lamotrigine 
was added to 50 ml of 2% (v/v) aqueous solution of 
Tween 80 as surfactant. For oily drug suspension, 
100 mg of drug was dispersed in 50 ml of liquid 
paraffin  containing  2  %  (v/v)  Span  80,  under 
continuous stirring (Mechanical Agitator–702 R, 
Remi equipments, Mumbai, India). 
Preparation of simple emulsions
Simple w/o emulsion was prepared by adding 20 
ml of aqueous drug dispersion gradually into 30 
ml of liquid paraffin containing 8% (v/v) Span 80 
under continuous stirring. Simple o/w emulsion was 
prepared by gradual addition of 20 ml of oily drug 
dispersion into 30 ml of distilled water containing 4% 
(v/v) Tween 80 under stirring. Stirring was carried 
out at 2000 rpm for 5 min at room temperature, for 
each case.
Preparation of multiple w/o/w emulsions 
Multiple w/o/w emulsions were prepared by both 
one step and two step emulsification methods (7). 
Multiple w/o/w emulsion by one step emulsification 
method
In one step emulsification method (8), lamotrigine 
was dispersed in aqueous phase containing 
hydrophilic surfactant and the lipophilic surfactant 
was mixed with oil phase. The total amount of both 
surfactants was kept at 5.0% (v/v) and their ratios 
were adjusted to achieve the effective hydrophilic 
lipophilic (EHLB) balance of 8.5 and 10.5. The 
oil and aqueous phases were heated separately up 
to 70±5°C. The aqueous phase was then slowly 
added to the oil phase under stirring at 4000 rpm 
till it reached room temperature. The effects of 
various formulation variables like concentration of 
polyvinyl alcohol (1%, 3% and 5% w/v) in aqueous 
phase, use of different oil phases (liquid paraffin, 
sunflower oil, soya bean oil) on drug release profiles 
were evaluated.
Multiple w/o/w emulsion by two step emulsification 
method 
First, 18 ml of aqueous drug dispersion was 
gradually introduced into 12 ml of liquid paraffin 
containing 8% (v/v) Span 80, under stirring at 
2000 rpm. In the second step, the resulting simple 
emulsion was dispersed into 20 ml of distilled water 
containing 2 % (v/v) Tween 80 by stirring at 1000 
rpm. For the preparation of multiple emulsions the 
same quantity of drug was distributed equally in 
both aqueous phases, drug quantity added in first 
step was reduced to half and the remaining half was 
added to the aqueous solution of 2 % (v/v) Tween 
80 in the second step of emulsification. Two types 
of multiple emulsions i.e. wd/o/w and wd/o/wd were 
prepared by this technique to evaluate the effect of 
location of drug (d) in the emulsion on drug release.
Evaluation of multiple emulsions
Stability  studies  of  multiple  emulsions  for 
sedimentation
In order to study the extent of sedimentation, the 
batches were transferred into a tightly corked 50 ml 
graduated measuring cylinder and stored at room 
temperature without disturbance. The volume of 
sediment was noted after 90 days. 
Morphological studies
The morphological characteristics (color, consistency 
and homogeneity) of multiple emulsions at the 
first  day  and  20  days  after  preparation  were 
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observed  microscopically  at  100X  magnification 
using Coaxial Binocular Microscope (LBM-1200, 
Labkron Instruments, Haryana, India) with inbuilt 
halogen light source. The w/o/w type of multiple 
emulsions was examined by introducing amaranth 
(water soluble red dye) in the internal aqueous phase. 
Entrapment efficiency
Entrapment efficiency (EE) of multiple 
emulsion was determined by centrifugation. The 
concentration of drug in the external aqueous phase 
separated on centrifugation was analyzed by UV 
spectrophotometer. The entrapment efficiency was 
calculated as follows:
EE=100-C            Equation 2
Where, C is the concentration of drug in the external 
aqueous phase expressed in percentage.
Polydispersity index and zeta potential 
The polydispersity index (PDI) and the zeta 
potential of the multiple emulsions were estimated 
using Master sizer (Malvern Instruments Ltd., 
Worcestershire, UK) after their dilution with filtered 
(0.22 microns) ultrapure water. 
Viscosity 
Viscosity measurements of the multiple emulsions 
were carried out at room temperature on a 
Brookfield  RVT  viscometer  (California,  USA)  at 
20, 50 and 100 rpm using spindle number of S62 at 
torque 0.5 Nm. 
Determination of thermal behavior by differential 
scanning calorimetry
Thermal behavior of multiple emulsion was studied 
using differential scanning calorimeter (DU-PONT, 
Model 9900, CA, USA) equipped with an intracooler 
and a refrigerated cooling system. Each sample was 
placed in an aluminium pan and was then crimped 
with an aluminium cover to provide hermetically 
sealed samples (1-2 mg). The heating rate was 10 
°C/min. The DSC thermograph of pure drug was 
obtained at a temperature range of 25 °C to 300 °C 
and that of multiple emulsion was measured at a 
temperature range of 0 °C to -45 °C. Nitrogen was 
purged at 50 ml/min through cooling unit. 
Batch Code
Drug 
(%w/v)
Surfactant blend (%v/v) Distilled water 
(%v/v)
Oil  phase (%v/v) PVA 
(%w/v) Tween 80 Span 80 LP SFO SBO
Multiple w/o/w emulsion for formula 
optimization by single step emulsification
C1  2 4 6 53 35 0 0 0
C2 2 4 6 63 25 0 0 0
C3 2 4 6 73 15 0 0 0
C4 2 6 4 53 35 0 0 0
C5 2 6 4 63 25 0 0 0
C6 2 6 4 73 15 0 0 0
aqueous drug suspension C7 2 1 0 100 0 0 0 0
oily drug suspension  C8 2 0 2 0 100 0 0 0
simple wd/o emulsion C9 2 0 8 40 60 0 0 0
simple od/w emulsion  C10 2 4 0 60 40 0 0 0
Multiple emulsion by two step 
emulsification (wd/o/w)
C11 2 4 6 73 15 0 0 0
Marketed formulation C12
Multiple emulsion with different PVA 
concentrations by one step emulsification
C13 2 4 6 72 15 0 0 1
C14 2 4 6 70 15 0 0 3
C15 2 4 6 68 15 0 0 5
Multiple emulsion with different oil 
phase by one step emulsification
C16 2 4 6 73 0 15 0 0
C17 2 4 6 73 0 0 15 0
C18 2 4 6 73 15 0 0 0
Multiple emulsion with drug (1:1) in 
both of water phases (wd/o/wd) by two 
step emulsification
C19 2 4 6 73 15 0 0 0
d- Indicates the presence of drug in that phase, LP, SFO and SBO indicate liquid paraffin, sunflower oil, soya bean oil, respectively.
Table 1: Formula for the preparation of aqueous and oily drug suspensions, simple (w/o and o/w) emulsion and different batches of drug 
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In vitro drug release studies
In vitro drug release study from aqueous and oily 
suspension, simple o/w emulsion, simple w/o 
emulsion and multiple w/o/w emulsion were 
carried out using diffusion cell technique (9). Test 
samples (10 ml) were placed in the diffusion cell 
of the donor compartment, separated with dialysis 
membrane from receptor compartment (250 ml 
beaker) containing 200 ml of the release medium. 
The release of lamotrigine from different batches 
was studied for a period of 12 hrs with 2 hrs in pH 
1.2, followed by next 2 hrs in pH 4.5 and finally for 
8 hrs in pH 7.4 buffers containing 2% (v/v) Tween 
80. The diffusion medium was stirred at 100 rpm at 
37±0.5 °C on a thermostatically controlled magnetic 
stirrer. Samples (5 ml) were withdrawn at different 
time intervals and analyzed spectrophotometrically 
and replaced with equivalent volume of the 
medium. The marketed formulation was available 
as dispersile tablet which was dispersed in 10 ml 
of water and the dispersion was placed in diffusion 
cell for drug release study. The release data for all 
batches were fitted to various models (Zero order, 
first order, Weibull, Higuchi, Peppas and Hixson-
Crowel models) to determine the mechanism of drug 
release (10). 
Determination of anticonvulsant activity in mice
The animal study protocol was duly approved by 
the Animal Ethical Committee, Banaras Hindu 
University. Albino mice (25±5 g), of either sex were 
randomly distributed into five different experimental 
groups. The mice were housed in groups of six 
(unless stated otherwise) in polypropylene cages 
at an ambient temperature of 25 ± 10 °C and 45-
55% relative humidity, with a 12:12 hrs light/dark 
cycle. Animals were provided with commercial 
food pellets with water ad libitum unless stated 
otherwise. Animals were acclimatized for at least 
one week before using them for experiments and 
exposed only once to an experiment. “Principles of 
laboratory animal care” (NIH publication number 
85-23, revised 1985) guidelines were followed. 
Anticonvulsant activity in terms of abolition of 
hind limb tonic extensor, latency to first convulsion, 
percent lethality, percent protection against maximal 
electroshock and strychnine induced seizure at 
different time intervals were studied in albino mice. 
The study was conducted by oral administration of 
the samples to five groups of mice (n=6) with three 
groups receiving test formulation Batch C11 at three 
dose levels i.e. 18 (T1), 36 (T2) and 54 (T3) µmol/
kg and the rest two groups receiving vehicle (control 
group) and the standard formulation (aqueous 
suspension of a dispersed tablet). The anticonvulsant 
activities of test samples were compared with that of 
the standard formulation and vehicle (control).
Maximal electroshock seizure (MES) test
This study was conducted after 60 min of dosing 
wherein the animals were stimulated by corneal 
electrodes for 0.2 sec using a Hugo Sachs stimulator 
(Type 207, Freiburg, FRG) with 50 mA and 60 Hz 
AC. The hind limb tonic extensor (HLTE) response 
10-12 s after stimulation was taken as the positive 
end point (11). The percentage protection against 
seizure was also measured at time intervals of 1, 2, 
4, 6 and 8 hrs. The percent protection against seizure 
provided by individual formulation was statistically 
compared (by applying Student’s t-test and is shown 
in each table) with respect to corresponding control 
(vehicle) and marketed formulation (standard). 
Strychnine induced seizure pattern test
In this test, strychnine (1-2 mg/kg, i.p.) in a volume 
of 0.01 ml/gm body weight was injected into the 
animals one hour post dosing and were observed 
for 10 min for onset and duration of tonic seizures. 
Abolition of the hind limb tonic extensor component 
was taken as the endpoint (11). 
RESULTS AND DISCUSSION
Solubility studies
Lamotrigine showed pH dependent solubility with 
higher solubility at lower pH. The solubility of the 
drug was found to be very low in distilled water 
(0.201± 0.004 mg/ml) and pH 7.4 (0.204±0.001 mg/
ml), and was high at pH 1.2 (2.235±0.146 mg/ml) 
and pH 4.5 (1.593±0.030 mg/ml). On addition of 
2% (v/v) Tween 80 to water the solubility increased 
by approx. ten folds (2.560±0.031 mg/ml) and was 
found to be comparable to that of citrate buffer (pH 
of 4.5). 
EHLB value studies
The volume fraction of the surfactant blends (v/v%)
for each required HLB was obtained from equation 
1. For EHLB of 8.5 and 10.5, Span 80 and Tween 80 
were required to be mixed at 60:40 and 41.78:58.22 
ratio, respectively.
Evaluation of multiple emulsion
Microscopic examination
The  photomicrographs  of  fresh  (first  day)  and 
4 weeks old samples of o/w and w/o emulsions 
are presented in figures 1 (A, B, C, and D). The 
micrographs of figure 1A (fresh) and 1B (4 weeks) of 
simple o/w emulsion show almost similar dispersed 
oil droplets. Similarly, photomicrographs of figure 
1C (fresh) and 1D (4 weeks) of simple w/o emulsion 
showed dispersed aqueous droplets throughout the 
continuous oil medium. The above observation 
suggests the stability of both emulsions.
The photomicrographs of fresh (day of 1) and 4 
weeks old samples of multiple w/o/w emulsions 
are  presented  in  figures  1E  and  1F,  respectively. 
The internal dispersed droplets were highly colored 
due to the presence of amaranth whereas color in controlled release liquid formulation of lamotrigine 130
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Figure 1: Photomicrographs of (A) freshly prepared simple o/w emulsion; (B) 4 weeks old simple o/w emulsion; (C) freshly prepared 
simple w/o emulsion; (D) 4 weeks old simple w/o emulsion; (E) freshly prepared multiple w/o/w emulsion and (F) 4 weeks old multiple 
w/o/w emulsion (100 X magnification).
the external continuous phase was negligible. The 
micrographs indicated the presence of many internal 
aqueous droplets within the oily droplets. The typical 
light scattering birefringence characters of liquid 
crystal layers were clearly visible at the periphery 
of the internal aqueous and intermediate oily 
dispersed droplets. All the above photomicrographs 
of simple and multiple emulsions clearly indicated 
that the emulsions were stable even upon storage 
for 4 weeks after preparation. 
Entrapment efficiency
The entrapment efficiency of different formulations 
(Table 2) varied from 84.37% - 98.11% depending 
upon surfactant concentration and the ratio of oil 
and aqueous phases. Ratio 40:60 (C1-C3) of tween 
80 and span 80 yielded higher entrapment efficiency 
in comparison to 60:40 ratios (C4-C6). In addition 
higher water/oil ratio was found to enhance the 
entrapment keeping the surfactant concentration 
constant i.e. C3 with water/oil ratio of 5.3 showed 
higher entrapment of the drug than C1 and C2 with 
water/oil ratio of 1.7 and 2.8, respectively. The 
high entrapment efficiency of these batches maybe 
attributed to the lipophilic nature of the drug which 
promotes the entrapment of drug in the oil phase. 
Zeta potential and polydispersity index
All formulations showed positive zeta potential 
values as can be seen in table 2. Zeta potential 
values of the emulsions were ranging from +23.46 
to +28.07 which indicate a stable formulation. The 
polydispersity indices were found to be in the range 
of 0.256 and 0.365 which indicates low droplet size 
distribution.
Rheological analysis
The viscosity of the w/o/w multiple emulsions was 
measured at three different rpm (20, 50 and 100 
rpm) and was found to decrease with increasing 
rate of shear stress (Table 2), which indicates 
non-Newtonian  flow  and  shear  thinning  behavior. 
Increase in external phase volume (aqueous phase) 
also decreased viscosity (12). Increase in hydrophilic 
surfactant concentration decreased the viscosity 
whereas  no  significant  difference  was  found  in 
viscosity as a function of lipophilic surfactant 
percentage (13). 
Some reports have described the bursting of 
multiple globules or phase inversion under shear 
stress (14, 15). However, such a phenomenon after 
viscosity measurement did not occur in this study, 
as it was determined by optical microscopy. It is 
concluded that shear stress of this study did not 
induce irreversible structural changes in multiple 
emulsions, such as coalescence or phase inversion.
DSC studies 
The DSC thermogram (Fig 2A) of the pure drug 
shows a sharp endothermic peak at 217.83°C with 
a melting enthalpy of 116.58 J/g. The thermogram Mishra et al / DARU 2011 19 (2) 126-137 131
of w/o/w emulsion (Fig 2B) with steady cooling 
shows two exothermic peaks typical to w/o/w 
multiple emulsions. The peaks demonstrate the 
presence of two aqueous phases, corresponding 
to  the  solidification  of  the  external  should  be 
deleted and the inner aqueous phases which took 
place at different temperatures due to the barrier 
effect of the intermediate oil phase. The presence 
of the inner aqueous phase was indicated by the 
appearance of a second peak in the DSC curve. 
Any further decrease in area under the second 
peak or its disappearance would indicate the inner 
water loss during storage, probably due to multiple 
droplets breakdown (16). During the thawing 
of the frozen sample, recorded between -60 and 
+25°C, only one endothermic signal was observed 
which means entire quantity of the water melts at     
0 °C (data not shown).
Stability  studies  on  different  batches  of  multiple 
emulsions
Macro and microscopical characteristics of the 
multiple emulsions are shown in table 2. The stability 
and morphology of multiple globules were found to 
be affected not only by the type and concentration of 
surfactant, but also by the water to oil ratios which 
were used. The stability of the emulsions increased 
with the increase in water to oil ratio. Samples 
were considered macroscopically stable for the 
period of study, since no signs of instability such 
as creaming and phase separation were observed. 
The sedimentation ratio of the prepared multiple 
emulsions were in the acceptable range of 0.88 to 
1.0. They were also considered microscopically 
stable, as the multiple droplet morphology showed 
no significant change during the pperiod of the study. 
It was observed that morphology of the multiple 
droplets  was  more  influenced  by  the  water/oil 
ratio than by the HLB values. Results of this study 
on stability are in agreement with earlier reports 
(8) where it was reported that most of the stable 
multiple droplets with Span and Tween series were 
obtained in samples with water/oil ratios varying 
from 2.8 to 18.0% (w/w).
In  vitro  drug  release  from  different  types  of 
formulations
Standard curve of the drug was found to be linear 
in the range of 5-30 μg/ml for both acidic buffer 
pH 1.2 (r2 =0.9997) and phosphate buffer pH 7.4 
(r2 =0.9989) having 2% (v/v) Tween 80 to maintain 
the sink condition. The in vitro release profiles from 
different  formulations  are  shown  in  figure.  The 
initial t10% (time for 10% cumulative drug release) 
values were found to be 2.05 hrs for aqueous drug 
suspension (C7), 3.24 hrs for oily drug suspension 
(C8), 3 hrs for o/w emulsion (C9), 3.17 hrs for w/o 
emulsion (C10) and 2.3 hrs for multiple w/o/w 
emulsion (C11) (Fig3). Burst release was not found 
in any of the formulation indicating proper loading of 
drug and absence of leakage from the formulations. 
Less than 20% of the drug was released in 4 hrs from 
formulations, and marketed product released drug to 
the extent of 40% in 4 hrs (C12). The t50% values of 
multiple w/o/w emulsions (8 hrs) were found to be 
less than that observed in the case of o/w emulsion 
(11.2 hrs) and w/o emulsion (12 hrs). 
The cumulative percent drug release was in the 
following  order;  marketed  formulation  >  aqueous 
drug suspension > multiple emulsion > simple 
o/w emulsion > oily drug suspension > simple w/o 
emulsion. The difference in drug release from the 
above formulations may be attributed to the dissolved 
or undissolved state of drug, hydrophobic nature of 
Batch code
Entrapment 
efficiency (%)
Zeta potential
Poly dispersity 
index
Viscosity(cps)
EHLB 
value
Macroscopic
properties
Microscopic
observation
w/o
ratio 20 
rpm
50 
rpm
100 
rpm
C1 87.44±4.87 28.07±1.59 0.327±0.03 7.9 5.9 4.8 8.49
White, highly 
viscous
Multiple 
droplets
1.7
C2 90.89±3.87 27.87±1.09 0.256±0.03 7.1 5.1 3.9 8.49
White, less viscous 
than C1
Multiple 
droplets
2.8
C3 98.11±3.55 25.34±1.21 0.287±0.02 6.8 4.8 3.0 8.49
White, less viscous 
than C2
Multiple 
droplets
5.3
C4 84.37±3.18 24.89±1.24 0.365±0.02 7.3 5.2 4.5 10.53
White,   more 
viscous than C3
Multiple 
droplets
1.7
C5 88.56±4.04 23.91±1.34 0.339±0.03 6.7 5.0 3.4 10.53
White, less viscous 
than C4
Multiple 
droplets
2.8
C6 90.65±3.78 23.46±1.17 0.310±0.02 6.2 4.9 2.5 10.53
White, less viscous 
than C5
Multiple 
droplets
5.3
Table 2: Physical characteristics of w/o/w multiple emulsion formulation (Mean±S.D, n=3).controlled release liquid formulation of lamotrigine 132
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Figure 3: In vitro release profiles of lamotrigine from aq. drug suspension (C7), oily suspension (C8), w/o emulsion (C9), simple o/w 
emulsion (C10), w/o/w multiple emulsion (C11), marketed formulation (C12) (Vertical bar represents S.D.).
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Figure 2: DSC thermogram of (A) pure drug and (B) w/o/w multiple emulsion (C11).
the oil phase, affinity or partitioning into aqueous 
or non aqueous phases. In the case of aqueous drug 
suspension, the drug release was found to be 1.3 
times higher than oily drug suspension which is due 
to the resistance offered by the oil phase to diffusion 
of drug into the release medium. In o/w emulsion, 
the drug is present in a suspended form in oil phase 
due to which negligible quantity of drug is available 
for partitioning between the oil and aqueous phases. 
Unlike w/o/w emulsion, the absence of pulling force 
from external surrounding resulted in slower rate 
of the drug release from o/w emulsion. However, 
drug release from o/w emulsion was higher than w/o 
emulsion which may be attributed to lower viscosity 
of o/w than w/o emulsion.
In the case of multiple emulsion, the external 
aqueous phase provides a gradient for the solubilized 
drug molecules present in the internal aqueous 
phase which is responsible for higher rate of drug 
release. Its lower viscosity is also an additional 
factor responsible for higher rate of drug release as 
compared to other formulations.
Effect  of  additives  on  drug  release  from  multiple 
emulsions
The in vitro drug release data of different multiple 
emulsions containing 1% (C13), 3% (C14) and 5% 
(C15) (w/v) PVA in internal aqueous phase of w/o/w Mishra et al / DARU 2011 19 (2) 126-137 133
emulsion  are  shown  in  figure  4.  The  initial  drug 
release from the formulations containing 3% and 
5% PVA were found to be similar as is evident from 
the t10% values (1.6 hrs for C14 and 1.5 hrs for C15). 
Burst release was not found in any formulation. 
More than 20% of drug was released in 3 hrs from 
all formulations except Batch C13. Presence of PVA 
in internal aqueous phase might have weakened the 
interfacial films resulting in higher drug release i.e. 
75% from the multiple emulsion (C15) as compared 
to 45% in multiple emulsion without additive (C11) 
in 7 hrs. 
Influence of oil phases on the release of lamotrigine 
from multiple emulsions
The in vitro release profiles from multiple w/o/w 
emulsions containing different oils, liquid paraffin 
(C16), sunflower oil (C17) and soya bean oil (C18), 
are shown in figure 5. The initial drug release from 
the formulations with sunflower oil (C17) and soya 
bean oil (C18) were found to be similar, probably 
due to the lack of appreciable difference in their 
viscosities (48.59 and 50.14 m Pa for soybean oil 
and sunflower oil, respectively) (17). This is evident 
from the t10% value which was found to be 2.85 hrs 
and 2.97 hrs for C17 and C18, respectively. With 
exception of batch C18, more than 20% of drug was 
released in 4 hrs from the other two formulations. 
The difference in drug release from formulation C16, 
C17 and C18 may again be attributed to viscosity 
of oil phase. Thus, it was inferred that the types of 
oil, its density and viscosity may influence the drug 
release characteristics from the multiple emulsions. 
A similar pattern has been reported for nitrofurantoin 
release from w/o/w emulsions formulated with soya 
and arachis oil (18). 
Effect  of  drug  location  on  release  of  lamotrigine 
from multiple emulsions
The  in  vitro  release  profiles  of  w/o/w  emulsions 
(fresh, two and four weeks old) containing entire 
drug in the internal aqueous phase (Batch C11) and 
equally distributed drug in internal and external 
aqueous phase in the ratio of 1:1, (Batch C19) are 
shown in figure 6. 
The t10% values were found to be 2, 3.87, 5.17, 
2.46 and 5.34 hrs for C11fresh, C112 weeks, C114 weeks, 
C19fresh and C194 weeks, respectively. In comparison 
to the batch C11fresh, batch C19fresh gave slower 
drug release probably for two reasons. First, since 
Batch C19fresh contained half quantity of drug in 
the external aqueous phase which was in direct 
contact with the diffusion membrane where release 
of this drug might have clogged the surface of the 
membrane by precipitating in acidic pH of the 
release medium which resulted in initial lower drug   
release. However, release was rapid later because of 
higher pH of the diffusion medium, which caused 
more diffusion of drug. In the case of the emulsion 
C11fresh, the possibility of precipitation appears to be 
negligible as it contained the total drug in internal 
aqueous phase and only little amount of the drug 
was available in external aqueous phase. In addition, 
as compared to C11fresh, the concentration gradient 
between the inner and external phases in emulsion 
C19fresh was lower due to distribution of the drug 
between the aqueous phases which resulted in lower 
drug release.
Figure 4: In vitro release profiles of lamotrigine from different multiple emulsions containing PVA 1% (C13), 3% (C14) and 5%                       
(C15) w/v (Vertical bar represents S.D.)
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Figure 5: In vitro release profiles of lamotrigine from different multiple emulsions containing liquid paraffin (C16), sunflower oil (C17) 
and soya bean oil (C18). (Vertical bar represents S.D.)
Drug release profile modeling
In order to understand the mechanism of drug 
release, data were fitted to different models (Table 
3). The best-fit model was selected on the basis of 
correlation coefficient (r) and the values of “K” and 
“n” which was shown by zero-order and Korsmeyer-
Peppas model. This clearly indicates that drug 
release from the formulation followed zero-order 
mechanism. 
Study of in vivo anticonvulsant activity in mice
Batch C11 at doses of 18 (T1), 36 (T2) and 54 
(T3) µmol/kg were tested for their anticonvulsant 
activity in mice (19). The results obtained from this 
formulation at different doses are shown in terms of 
seizure latency duration, percent protection against 
seizure and lethality in both MES (Table 4) and 
strychnine induced convulsion (Table 5) whereas 
figure  7  shows  seizure  latency  calculated  with 
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Figure 6: In vitro release profiles of lamotrigine from freshly prepared wd/o/w emulsions (C11fresh), 4 weeks old wd/o/w emulsions 
(C114 weeks), freshly prepared wd/o/wd emulsions (C18 fresh) and 4 weeks old wd/o/wd emulsions (C184 weeks). d- Indicates presence 
of drug in that phase. (Vertical bar represents S.D.)
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respect to control (vehicle). 
MES induced seizures in mice
The results of this study are summarized in table 
4. Batch T1, T2 and T3 exhibited 83.34%, 100% 
and 100%, respectively, protection against seizure 
from hind limb tonic extensor induced by MES. The 
standard group (group administered with marketed 
formulation at the dose level of 36 μmol/kg) also 
exhibited 100 % protection against MES induced 
HLTE phase. Mortality and lethality of T2 was also 
recorded at 1, 2, 4, 6 and 8 hrs. Percent protection 
against seizure by T2 and standard in 1, 2, 4, 6 and 
8 hrs exhibited (100%, 100%), (100%, 78.64%), 
Figure 7: w/o/w emulsion (T2) showing prolonged anticonvulsant effect.
31 
 
 
Figure 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100
80
60
40
20
0
%
 
P
r
o
t
e
c
t
i
o
n
 
a
g
a
i
n
s
t
 
s
e
i
z
u
r
e
Time (hrs)
1               2               3                4                 5  
Model
BATCH CODE
C11(C3) C13 C14 C15 C16 C17 C18
Zero order
r2 0.990 0.991 0.987 0.990 0.988 0.993 0.989
kZ 6.151 7.029 9.925 11.03 5.04 3.23 5.749
First order
r2 0.866 0.874 0.822 0.813 0.735 0.881 0.846
kF 0.135 0.170 0.170 0.174 0.181 0.204 0.153
Higuchi model
r2 0.751 0.871 0.910 0.908 0.743 0.882 0.856
kH 22.76 26.87 38.17 42.58 13.51 9.499 21.78
Weibull model
r2 0.861 0.792 0.892 0.895 0.880 0.751 0.686
β 1.103 1.457 1.518 1.60 1.415 1.502 1.251
Td 1.73 2.25 1.98 6.79 3.09 1.95 2.42
Peppas model
r2 0.927 0.984 0.892 0.896 0.942 0.954 0.990
kP 0.062 0.073 0.105 0.059 0.016 0.08 0.041
n 0.876 0.914 0.885 0.923 0.953 0.945 0.881
Hixon-Crowel model
r2 0.924 0.779 0.855 0.860 0.764 0.927 0.881
kHC 0.024 0.028 0.045 0.052 0.012 0.008 0.022
f1 26.73 12.13 22.06 26.29 31.87 25.81 11.56
f2 39.56 72.63 50.21 66.34 49.08 65.73 72.18
C11 and C3 have similar formula but were prepared by two and one step emulsification techniques, respectively
Table 3: Kinetics of drug release from different batches of multiple emulsions
(100%, 66.67%), (83.34%, 55.67%) and (50%, 
33.34%), respectively. From the percent protection 
against seizure vs. time data, it was concluded that 
T2 batch exhibited more prolonged anticonvulsant 
activity than marketed formulation used as standard 
and was significantly different from control (vehicle) 
(p<0.01, n=6) as shown in figure 7. 
Strychnine induced convulsions in mice
Strychnine induced seizures were characterized 
by tremors and straub tail followed by myoclonic 
jerks of the limbs, leading to full generalized clonic/
tonic seizures. Generally, death occurred within 
few minutes of the onset of clnic/tonic seizures or, controlled release liquid formulation of lamotrigine 136
Treatment
(No of animals)
Dose (µmol/kg) Seizure latency (seconds) Duration (seconds) Animal HLTE (x/y)
% Protection
against seizure
Vehicle (6) _ 10.2±0.39 21.8±2.36 6/6 0
T1 (6) 18 8.65±1.26 25.9±3.26 5/6 83.34*
T2 (6) 36 _ _ 0/6 100*
T3 (6) 54 _ _ 0/6 100*
Standard(6) 36 _ _ 0/6 100*
HLTE: Hind Limb Tonic Extensor. Vehicle was used as control. Where, x/y indicates ratio between number of non protected animals 
and number of animals which were used. (-) indicates as there was 100% protection, so no seizure latency. * Significantly different 
from control (vehicle) (p<0.01, n=6).
Treatment
(No of animals)
Dose (µmol/kg) Seizure latency (secs) Clonic/Tonic Seizures Lethality
% Protection 
against seizure
Vehicle (6) _ 67.54±4.8 6/6 6/6 0
T1 (6) 18 272.50±18.21 6/6 6/6 0
T2 (6) 36 314.83±22.98 4/6 4/6 66.67*
T3 (6) 54 425.33±23.73 5/6 5/6 83.34*
Standard (6) 36 600 ±0 0/6 0/6 100*
Seizure latency is the time required to start seizure. Lethality was estimated as the ratio between number of dead animals and number 
of animals showing convulsions. * Significantly different from control (vehicle) (p<0.01, n=6).
Table 4: Effect of lamotrigine formulations on maximal electroshock induced seizure (MES) test in mice.
Table 5: Effect of lamotrigine formulations on strychnine induced lethal seizure in mice.
in any case, within one hour. Vehicle and T1 failed 
to protect the mice from generalized clonic-tonic 
convulsions induced by strychnine. However, batch 
T2, T3 and standard formulation exhibited 66.67%, 
83.34% and 100% protection against seizure, 
respectively, against generalized clonic-tonic 
seizures induced by strychnine in mice and the effect 
was  significantly  different  from  control  (vehicle) 
(p<0.01, n=6) as shown in table 5. From the percent 
protection against seizure data, it was concluded 
that T3 batch exhibited comparable anticonvulsant 
activity against strychnine induced seizures as that 
of marketed formulation. 
CONCLUSION
Multiple emulsions (w/o/w) were found to be 
suitable for the development of controlled release 
delivery systems for poorly water soluble drug 
like lamotrigine.  Two promising w/o/w multiple 
emulsions prepared using optimized EHLB at 8.49 
and  10.53  by  one  step  emulsification  technique 
exhibited  anticonvulsant  effect  for  sufficiently 
prolonged duration of time as compared to marketed 
formulation.  The w/o/w multiple emulsions, by 
virtue of their sustained release characteristics, may 
avoid plasma drug level fluctuation, maintain plasma 
drug concentrations within therapeutic range for 
longer time and thereby reduce the onset of adverse 
events. Due to its liquid state, it may be used as a 
convenient and suitable dosage form for pediatric 
and geriatric patients and as a result may increase 
patient compliance. 
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